Project Grant R43DK145239
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- This federal Project Grant award in the amount of $1,428,186.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Massachusetts. The project aims to investigate the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans, which has implications for understanding the early...
- This $2,060,811 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on the role of activin type II receptor signaling in muscle hypertrophy, obesity, and weight loss. The research aims to understand how blocking the activin type II receptor can preserve lean muscle mass while maximizing fat loss during obesity treatment,...
- This $3,065,252 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project aims to develop engineered metabolite-based nanoparticles for immunomodulation of macrophages to treat obesity, a critical health concern due to its links to metabolic diseases. The Terasaki Institute for Biomedical Innovation, a non-profit research...
- This federal Project Grant award of $813,511 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research at the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the structural basis and functional consequences of thermogenic mitochondrial respiratory complexes assembly in the context of obesity and type 2 diabetes. The research aims to...
- This federal Project Grant award of $803,748 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is funding research to investigate the modulation of insulin signaling in adipocytes (fat cells) and how improved adipocyte insulin sensitivity can contribute to positive metabolic outcomes. The research team at The University of Texas Southwestern Medical...
- This Project Grant award of $830,500.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports research investigating the role of glycosphingolipids in kidney disease associated with diabetes and obesity. The key objectives are to: Test whether inhibiting glucosylceramide synthesis in podocytes, renal tubules, or the immune system can prevent progression of kidney disease in mouse...
- This Project Grant award of $307,508 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a novel bioengineered brown adipocyte (fat cell) transplant as a potential new therapy for treating obesity and associated metabolic disorders. The award will fund research by United Biotherapeutics LLC to further develop a safer and more efficient adeno-associated...
- This $659,199 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to investigate a novel pathway by which hepatocyte-derived growth differentiation factor 15 (GDF15) can improve obesity-associated insulin resistance independent of changes in body weight. The research aims to characterize this GFRAL-independent mechanism and determine the stress signaling pathways...
This federal Project Grant award of $350,000 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The objective is to validate the use of AVGN7 (rAAV6:SMAD7), a gene therapeutic, for treating obesity and type 2 diabetes mellitus (T2DM). The key products or services to be delivered include: (1) Demonstrating that AVGN7 can restore lean body mass and insulin sensitivity in obese mice fed a high-fat diet, and (2) Preventing the development of obesity and T2DM in animal models. The award was made to Aavogen Inc., a biotechnology company in Rockville, Maryland focused on developing advanced gene therapeutic technologies. The project period runs from September 5, 2025 to September 4, 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $350.0k | 9/5/25 |